non-completion of planned salpingectomy. MRS scores were compared using paired t-tests. RESULTS: Among 70 patients offered enrollment in this study, 67 (96%) consented, and complete data are available for 62 (93%). Mean age was 51.1 years (AE 9.4). Median body mass index (BMI) was 27.1 kg/m2; median vaginal parity was 2 (0-4), and 43% were postmenopausal. The primary indication for hysterectomy was prolapse (76%), heavy menstrual bleeding (18%), and other (6%). Vaginal salpingectomy was successfully performed in 46/62 (74%) women. Mean operating time for bilateral salpingectomy was 11 minutes (AE 5.7), with additional mean EBL of 6 cc (AE 17.3). There were 8 surgical complications: 3 hemorrhages > 500 ml and 5 conversions to alternate routes of surgery, but none of these were due to the salpingectomy. Mean uterine weight was 68 grams and there were no abnormalities on fallopian tube pathology. Among the 16 patients in whom planned bilateral salpingectomy was not completed, unilateral salpingectomy was performed in 6 and both tubes were left in situ in 10. Reasons for non-completion of salpingectomy included: tubes were too high in the pelvis (7), conversion to alternate route for pathology (2), ovarian adhesions (2), bowel or sidewall adhesions (3), no reason (1), and ovarian pathology requiring oophorectomy (1). There were no identified risk factors for unsuccessful salpingectomy including age (p ¼ 0.05), BMI (p ¼ 0.68), and prior tubal ligation (p ¼ 0.052). Mean MRS scores did not significantly change from preoperatively to postoperatively (9.85 vs 6.04, p ¼ 0.61). CONCLUSION: Vaginal salpingectomy is feasible in the majority of women undergoing planned vaginal hysterectomy and increases operating time by 11 minutes and EBL by 6 cc. Risk factors for unsuccessful removal could not be identified.
OBJECTIVES: Many gynecologic, urologic and pelvic reconstructive surgeries require accurate intra-operative evaluation of ureteral patency. The objective of this study is to compare surgeon satisfaction with four methods of evaluating ureteral patency at the time of cystoscopy: phenazopyridine, sodium fluorescein, mannitol, and normal saline.
MATERIALS AND METHODS:
We conducted a randomized controlled trial of the method used to evaluate ureteral patency during cystoscopy at time of benign gynecologic or pelvic reconstructive surgery. Subjects were randomized to 200 mg oral phenazopyridine, 25 mg sodium fluorescein intravenously, mannitol bladder distention, or normal saline bladder distention during cystoscopy to evaluate ureteral patency. The primary outcome was surgeon satisfaction with the method, which was assessed via a 10 cm Visual Analog Scale (VAS). A priori sample size of 137 participants was planned to detect a 3 cm difference in the VAS scale with 80% power and a 2-tailed alpha of 0.05, including 10% added for participant dropout. Demographic and operative information, including time to confidence in the ureteral jets was collected. Adverse events were followed for at least 6 weeks after the surgical procedure. RESULTS: Two hundred nine patients were screened for eligibility, 193 met inclusion criteria, and 140 were consented and enrolled in the study. One hundred thirty subjects were randomized and evaluated according to intention-to-treat into four groups: phenazopyridine (n ¼ 33), sodium fluorescein (n ¼ 32), mannitol (n ¼ 32), and normal saline (n ¼ 33). Demographics were similar between groups with mean/standard deviation age of 50 years (12) and BMI 29 (7), and median/range parity 2 (0, 8). Forty-two percent were Hispanic, 31% white, 19% African American, 2% Asian, and 6% unknown/other. Indications for surgery were similar across groups and included AUB/fibroids (48%), prolapse (28%), incontinence (12%), and microhematuria (4%). Type of surgery did not differ across groups and included 55% hysterectomy, 42% pelvic reconstruction, and 26% incontinence surgery. With regard to the primary outcome, mannitol was noted to be the most satisfactory method to physicians for assessing ureteral patency (p < 0.001). Mannitol was also the easiest method to use and the agent that provided the clearest and most definitive visualization of the ureteral jets, bladder mucosa and urethra (all p < 0.001). Surgery length, cystoscopy length, and time to confidence in ureteral jets were not different between groups (all p > 0.05). During the 111 day median followup, there was no significant difference in adverse events noted among the groups, including urinary tract infections (all p > 0.05). CONCLUSION: The use of mannitol during cystoscopy to assess ureteral patency provided surgeons with the most overall satisfaction, ease of use, and superior visualization without impacting surgery or cystoscopy times. There were no differences in adverse events, including urinary tract infections.
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14 Impact of liposomal bupivacaine on pain following retropubic midurethral sling placement: A randomized placebo-controlled trial OBJECTIVES: Midurethral slings are commonly used to treat stress urinary incontinence. Pain control, however, may be a concern. We sought to examine the impact of liposomal bupivacaine (LB), a local anesthetic with slow release over 72 hours, on pain scores following retropubic midurethral sling placement. MATERIALS AND METHODS: This randomized, placebo-controlled trial enrolled women undergoing retropubic midurethral slings with or without concomitant anterior or urethrocele repair under general anesthesia. Subjects were allocated to receive LB or normal saline placebo (P) injected into the trocar paths and vaginal incision at the conclusion of the procedure. At the time of drug administration, surgeons became unblinded, but did not collect outcome data. Participants remained blinded to treatment. Surgical procedures and perioperative care were standardized. The primary outcome was Visual Analog Scale (VAS) pain score 4 hours after discharge home. Secondary outcomes included narcotic consumption, time to first bowel movement, and VAS pain scores collected in the mornings and evenings until postoperative day (POD) 6. The morning VAS item assessed "current level of pain," and evening items queried "current level of pain," "most intense pain today," "average pain today with activity," and "average pain today with rest." Likert scales were used to measure satisfaction with pain control at 1 and 2 week postoperative intervals. Sample size calculation deemed 52 subjects per arm necessary to detect a mean difference of 10 mm on 100 mm VAS. To account for 10% drop out, 114 participants were needed. RESULTS: One hundred fourteen women were enrolled. After 5 exclusions, 109 were analyzed: 54 received LB, and 55 received P. Mean participant age was 52 years, and mean BMI was 30.4. Surgical and demographic characteristics were similar except a slightly higher BMI in the P arm (31.6 vs 29.2, p ¼ 0.050), and more subjects received midazolam during anesthesia induction in the LB arm (52 vs 44, p ¼ 0.015). For the primary outcome, the VAS pain score (mm) was lower in the LB group 4 hours after discharge home (3.5 vs 13, p ¼ 0.014). VAS scores were also lower for LB subjects at the following collected time points: POD 1 morning "current level of pain" (9.5 vs 27, p ¼ 0.014), POD 2 "average pain with rest" (5.5 vs 10, p ¼ 0.027), POD 3 morning "current level of pain" (6 vs 10, p ¼ 0.011), and POD 3 "average pain with rest" (4 vs 7, p ¼ 0.043). Furthermore, fewer LB participants consumed narcotic medication on POD 2 (12 vs 27, p ¼ 0.006). There was no difference in satisfaction with pain control between groups. Side effects experienced, rate of postoperative urinary retention, and time to first bowel movement were also similar between arms. Finally, no serious adverse events were noted. CONCLUSION: Liposomal bupivacaine decreased postoperative pain scores following retropubic midurethral sling placement. Participants who received liposomal bupivacaine were also less likely to use narcotics on POD 2. No differences in side effects or adverse events were observed between groups. For this common outpatient surgery, liposomal bupivacaine may be a beneficial addition for pain control. OBJECTIVES: Liposomal bupivacaine is an extended-release, local subcutaneous anesthetic preparation providing up to 72 hours of pain relief. However, few studies have evaluated its use in pelvic reconstructive surgery.

MATERIALS AND METHODS:
This was a prospective, randomized, patient-blinded, placebo-controlled trial of patients undergoing robotic-assisted sacrocolpopexy with rectocele repair. Either liposomal bupivacaine or normal saline was injected subcutaneously into laparoscopic port sites and posterior repair incision at the completion of surgery. Perioperative care was standardized for both groups. Visual analog scales (VAS) were collected in the hospital at 4, 18, and 24 hours following surgery. Upon discharge, participants were asked to complete twice daily VAS questionnaires and a pain medication diary until postoperative day 3. The primary outcome was VAS for pain 18 hours after surgery. Secondary measures included nursing administered verbal pain scores, satisfaction with pain control, narcotic use (morphine equivalents), location of "the most painful" site, voiding trial results, and time to first bowel movement. Our sample size calculation revealed 32 subjects per arm were required to detect a mean difference of 20 mm on the Visual Analog Scale (VAS). To allocate for dropout, a goal of 70 was set. RESULTS: Seventy patients were enrolled; 6 were excluded: 2 converted to vaginal repairs, 2 withdrew after randomization, 1 patient had an elevated creatinine, and 1 reported a history of cocaine abuse. Sixty-four subjects were analyzed: 33 received liposomal bupivacaine (LB) and 31 received normal saline (NS). The mean age was 62 (SD 13), and mean body mass index was 27.3 (SD 6.9). There was no difference in demographics, surgical data, voiding trial results, time to first bowel movement, or satisfaction scores between the cohorts. While the median VAS score at 18 hours after surgery was lower for those who received liposomal bupivacaine ( When comparing all abdominal incisions, participants noted the umbilical site to be the most painful. However, there was no significant difference between overall abdominal incision pain and vaginal incision pain among or between groups. Most common reported side effects included nausea, itching, insomnia, and irritation at the injection sites, with no differences based on treatment allocation. CONCLUSION: In this study of robotic assisted sacrocolpopexy with rectocele repair, there was no significant difference in VAS scores or narcotic use between liposomal bupivacaine and normal saline for local analgesia. A modest benefit was noted only in nursing administered pain scores. Given potential increased expense and risk of adverse events with liposomal bupivacaine, we do not support its routine use for this surgical intervention.
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16 Validation of a hybrid technique for minimally invasive myomectomy R. P. Baxi, L. van der Does, P. Mackoul, N. Danilyants, L. Haworth
Minimally Invasive Gynecological Surgery, Center for Innovative Gyn Care, Rockville, MD OBJECTIVES: Laparoscopic myomectomy (LM) is considered the gold standard for surgical management of uterine leiomyoma; however, when compared to abdominal myomectomy, it is associated with prolonged operative time (OT), higher cost, risk of leiomyoma recurrence and weaker uterine defect repair. The purpose of this study is to compare surgical outcomes of commonly performed
